693235-85-7Relevant articles and documents
Development, synthesis and biological investigation of a novel class of potent PC-PLC inhibitors
Barker, David,Langley, Ries J.,Leung, Euphemia,Leung, Ivanhoe K. H.,Paulin, Emily K.,Pilkington, Lisa I.,Rees, Shaun W. P.,Reynisson, Jóhannes,Sparrow, Kevin,Xu, Chris Sun,van Rensburg, Michelle
, (2020/02/27)
Phospholipases are enzymes that are involved in the hydrolysis of acyl and phosphate esters of phospholipids, generating secondary messengers that have implications in various cellular processes including proliferation, differentiation and motility. As such inhibitors of phospholipases have been widely studied for their use as anti-cancer therapeutics. Phosphatidylcholine-specific phospholipase C (PC-PLC) is implicated in the progression of a number of cancer cell lines including aggressing triple-negative breast cancers. Most current studies on PC-PLC have utilised D609 as the standard inhibitor however it is known to have multiple failings, including poor stability in aqueous media. 2-Morpholinobenzoic acids were recently identified using vHTS as a potential class of lead compounds, with improvements over D609. In this work 129 analogues in this class were prepared and their PC-PLC inhibitory activity was assessed. It was found that the majority of these novel compounds had improved activity when compared to D609 with the most potent inhibitors completely inhibiting enzyme activity. It was determined that the best compound/s contained a morpholino and 2-substituted N-benzyl moieties with these findings explained using molecular modelling. The compounds reported here will allow for improved study of PC-PLC activity.
